119 related articles for article (PubMed ID: 37080942)
1. First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Doi T; Matsubara N; Naito Y; Kuboki Y; Harano K; Ono M; Urasaki T; Ohmoto A; Kawanai T; Hisai T; Ikezawa H; Shiba S; Ito K; Semba T; Asano O; Takahashi S
Cancer; 2023 Aug; 129(15):2348-2359. PubMed ID: 37080942
[TBL] [Abstract][Full Text] [Related]
2. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
[TBL] [Abstract][Full Text] [Related]
3. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
4. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.
Tabernero J; Bedard PL; Bang YJ; Vieito M; Ryu MH; Fagniez N; Chadjaa M; Soufflet C; Masson N; Gazzah A
Cancer Res Commun; 2023 Aug; 3(8):1662-1671. PubMed ID: 37645622
[TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Gazzah A; Bedard PL; Hierro C; Kang YK; Abdul Razak A; Ryu MH; Demers B; Fagniez N; Henry C; Hospitel M; Soria JC; Tabernero J
Ann Oncol; 2022 Apr; 33(4):416-425. PubMed ID: 35026412
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.
Liu D; Ma C; Lu P; Gong J; Ye D; Wang S; Peng P; Bai Y; Song Y; Chen J; Jiang O; Zhang G; Ba Y; Chen L; Pan J; Li Q; Zhang L; Gu S; Yin X; Cao B; Han W; Dong H; Guo J; Zhang H; Su H; Jiang Y; Ouyang W; Ma L; Sun Y; Zhang F; Lv J; Guo Y; Xu C; Qi J; Wang L; Wang X; Liu Z; Shen L
Eur J Cancer; 2021 May; 148():1-13. PubMed ID: 33691262
[TBL] [Abstract][Full Text] [Related]
7. A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Chiorean EG; LoRusso P; Strother RM; Diamond JR; Younger A; Messersmith WA; Adriaens L; Liu L; Kao RJ; DiCioccio AT; Kostic A; Leek R; Harris A; Jimeno A
Clin Cancer Res; 2015 Jun; 21(12):2695-703. PubMed ID: 25724527
[TBL] [Abstract][Full Text] [Related]
8. AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
Frentzas S; Kao S; Gao R; Zheng H; Rizwan A; Budha N; de la Hoz Pedroza L; Tan W; Meniawy T
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857528
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
Baranda JC; Robbrecht D; Sullivan R; Doger B; Santoro A; Barve M; Grob JJ; Bechter O; Vieito M; de Miguel MJ; Schadendorf D; Johnson M; Pouzin C; Cantalloube C; Wang R; Lee J; Chen X; Demers B; Amrate A; Abbadessa G; Hodi FS
Clin Transl Sci; 2024 Jun; 17(6):e13854. PubMed ID: 38898592
[TBL] [Abstract][Full Text] [Related]
10. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
11. Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.
Shiah HS; Chiang NJ; Lin CC; Yen CJ; Tsai HJ; Wu SY; Su WC; Chang KY; Wang CC; Chang JY; Chen LT
Oncologist; 2021 Apr; 26(4):e567-e579. PubMed ID: 33245172
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Shapiro GI; LoRusso P; Cho DC; Musib L; Yan Y; Wongchenko M; Chang I; Patel P; Chan IT; Sanabria-Bohorquez S; Meng RD; Bendell JC
Invest New Drugs; 2021 Feb; 39(1):163-174. PubMed ID: 32737717
[TBL] [Abstract][Full Text] [Related]
13. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities.
Ito K; Yamaguchi M; Semba T; Tabata K; Tamura M; Aoyama M; Abe T; Asano O; Terada Y; Funahashi Y; Fujii H
Mol Cancer Ther; 2024 Feb; 23(2):235-247. PubMed ID: 37816248
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of the VEGF/Ang-2 inhibitor BI 836880 alone or combined with the anti-programmed cell death protein-1 antibody ezabenlimab in Japanese patients with advanced solid tumors.
Yamamoto N; Koyama T; Shimizu T; Todaka A; Kawakami T; Erzen D; Sarashina A; Li B; Hou J; Yamazaki K
Cancer Chemother Pharmacol; 2023 Jun; 91(6):469-480. PubMed ID: 37140602
[TBL] [Abstract][Full Text] [Related]
16. A phase I dose-escalation and pharmacokinetic study of a micellar nanoparticle with entrapped docetaxel (CPC634) in patients with advanced solid tumours.
Atrafi F; Dumez H; Mathijssen RHJ; Menke van der Houven van Oordt CW; Rijcken CJF; Hanssen R; Eskens FALM; Schöffski P
J Control Release; 2020 Sep; 325():191-197. PubMed ID: 32590047
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors.
Ma Y; Xue J; Zhao Y; Zhang Y; Huang Y; Yang Y; Fang W; Guo Y; Li Q; Ge X; Sun J; Zhang B; Zhang Y; Xiao J; Zhang L; Zhao H
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37263673
[TBL] [Abstract][Full Text] [Related]
18. Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.
Le Tourneau C; Becker H; Claus R; Elez E; Ricci F; Fritsch R; Silber Y; Hennequin A; Tabernero J; Jayadeva G; Luedtke D; He M; Isambert N
ESMO Open; 2022 Oct; 7(5):100576. PubMed ID: 36108560
[TBL] [Abstract][Full Text] [Related]
19. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
20. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
Liu D; Zhou J; Wang Y; Li M; Jiang H; Liu Y; Yin X; Ge M; Xiang X; Ying J; Huang J; Zhang YQ; Cheng Y; Huang Z; Yuan X; Han W; Yan D; Wang X; Liu P; Wang L; Zhang X; Luo S; Liu T; Shen L
BMC Med; 2022 Oct; 20(1):408. PubMed ID: 36280870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
